[1] WHO website, http://www.who.int/cancer/en.html. Last assessed 13 July 2016.
[2] Oncology: treatment and management. Part 2, Cancer treatment. Pharmaceutical representative, November 2002
[3] Feng SS, Chien S. Chemotherapeutic engineering: Application and further development of chemical engineering principles for chemotherapy of cancer and other diseases. Chem Eng Sci 2003; 58: 4087-4114.
[4] Ehrlich P. Chemotherapeutics: Scientific principles, methods and results. Lancet 1913; 182(4694): 445-451.
[5] http://www.cancer.org/acs/groups/content/@research/documents/document/acspc-047079.pdf; last assessed 13 July 2016.
[6] Lisa Brannon-Peppas. Polymers in controlled drug delivery. Medical Plastics and Biomaterials 1997; 4: 34-45.
[7] Mu L, Feng SS. A novel controlled release formulation for the anticancer drug paclitaxel (Taxol): PLGA nanoparticles containing vitamin E TGPS. J Control Release 2003; 86(1): 33-48.
[8] Silverberg E, Boring CC, Squires TS. Cancer statistics. CA Cancer J Clin 1990; 40(1): 9-26.
[9] http://en.wikipedia.org/wiki/Lung_cancer; last accessed 27 August 2015.
[10] Zhou F, Zhou Cai-Cun. Targeted therapies for patients with advanced NSCLC harboring wild-type EGFR: what’s new and what’s enough. Chinese J Cancer 2015; 34: 31-41.
[11] Ely L, Roa W, Finlay WH, Lobenberg R. Effervescent dry powder for respiratory drug delivery. Eur J Pharm Biopharm 2007; 65(3): 346-353.
[12] Quattrin T. Inhaled insulin: recent advances in the therapy of Type 1 and 2 diabetes. Expert Opin Pharmacother 1992; 8: 2597-2604.
[13] Patton JS, Platz RM. Pulmonary delivery of peptides and proteins for systemic action. Adv Drug Deliv Rev 1992; 8: 179-196.
[14] Edwards DA, Hanes J, Caponetti G, Hrkach J, Ben-Jebria A, Eskew ML, Mintzes J, Deaver D, Lotan N, Langer R. Large porous particles for pulmonary drug delivery. Science 1997; 276: 1868-1871.
[15] Tsapis N, Bennett D, Jackson B, Weitz DA, Edwards DA. Trojan particles: large porous carriers of nanoparticles for drug delivery. Proc Natl Acad Sci 2002; 99: 12001-12005.
[16] Taylor G, Kellaway I. Pulmonary drug delivery. In: Hiller A, Lloyed A, Swarbricks J, eds. Drug Delivery and Targeting, New York: Taylor & Francis, 2001: 269-300.
[17] Lorenzer C, Dirin M, Winlker A-M, BaumannV, Winlker J. Going beyond the liver: progress and challenges of targeted delivery of siRNA therapeutics. J Control Release 2015; 203: 1-10.
[18] Kreuter J, Tauber U, Illi V. Distribution and elimination of poly (metyl-2-14C-methacrylate) nanoparticle radiaoactivity after injection in rats and mice. J Pharm Sci 1979; 68(11): 1443-1447.
[19] Kreuter J. Evaluation of nanoparticles as drug-delivery systems III: materials, stability, toxicity, possibilities of targeting and use. Pharm Acta Helv 1983; 58(9-10): 242-250.
[20] Huo D, Deng S, Li L, Ji J. Studies on the poly(lactic-co-glycolic) acid microspheres of cisplatin for lung-targeting. Int J Pharm 2005; 289: 63-67.
[21] Tao Y, Zhang HL, Hu YM, Wan S, Su ZQ. Preparation of chitosan and water soluble chitosan microspheres via spray drying method to lower blood lipids in rats fed with high-fat diet. Int J Mol Sci 2013; 14(2): 4174-4184.
[22] Ozkan Y, Diken M, Isimer A. Clarithromycin targeting to lung: optimization of size, morphology and release characteristics of albumin microspheres. Acta Pol Pharm – Drug Res 2000; 57(5): 375-380.
[23] Eldem T, Spieser P, Hincal A. Optimization of spray-dried and –congealed lipid micropellets and characterization of their surface morphology by scanning electron microscopy. Pharm Res 1991; 8: 47-54.
[24] Zhang Z, Chen J, Ding L, Jin H, Lovell JF, Corbin IR, Cao W, Lo PC, Yang M, Tsao MS, Luo Q, Zheng G., HDL-mimicking peptide-lipid nanoparticles with improved tumor targeting. Small Weinheim Bergstrasse Ger 2010; 6(3): 430–437
[25] Gipps EM, Arshady R, Kreuter J. Distribution of polyhexyl cyanoacrylate nanoparticles in nude mice bearing human osteosarcoma. J Pharm Sci 1986; 75 (3): 256-258.
[26] Kellaway IW, Farr SJ. Liposomes as drug delivery systems to lung. Adv Drug Del Rev 1990; 5: 149-161.
[27] Waser PG, Muller U, Kreuter J, Berger S, Munz K, Kaiser E, Pfluger B. Localization of colloidal particles (liposomes, hexylcyanoacrylate nanoparticles and albumin nanoparticles) by histology and autoradiography in mice. Int J Pharm 1987; 39: 213-227.
[28] Leucauta SE, Achim M, Risca R, Pstescu ID. Preparation and pharmaceutical/pharmacokinetic characterization of liposomes and nanoparticles loaded with epirubicin. STP Pharm Sci 2013; 13(5): 291-297.
[29] Zara GP, Cavalli R, Fundaro A, Bargoni A, Caputo O, Gasco MR. Pharmacokinetics of doxorubicine incorporated in soid lipid nanoshpheres. Pharmacol Res 1999; 40(3): 281-286.
[30] Lobenberg R, Araujo L, Von Briesen H, RodgersE, Kreuter J. Body distribution of azidothymidine bound to hexyl-cyanoacrylate nanoparticles after i.v. injection to rats. J Control Release 1998; 50(1-3): 21-30.
[31] Santhi K, Dhanaraj SA, Koshy M, Ponnusankar S, Suresh B. Study of biodistribution of methotrexate loaded bovine serum albumin nanospheres inmice. Drug Dev Ind Pharm 2000; 26(12): 1293-1296
[32] Xiang QY, Wang MT, Chen F, Gong T, Jian YL, Zhang ZR, Huang Y. Lung-targeted delivery of dexamethasone acetate loaded solid lipid nanoparticles. Arch Pharm Res 2007; 30(4): 519-525.
[33] Bazile DV, Ropert C, Huve P, Verrecchia T, Marlard M, Frydman A, Veillard M, Spenlehauer G. Body distribution of fully biodegradable [14C]-poly (lactic acid) nanoparticles coated with albumin after parenteral administration to rats. Biomaterials 1992; 13(15): 1093-1102.
[34] Simon BH, Ando HY, Gupta PK. Circulation time and body distribution of 14C-labeled amino-modified polystyrene nanoparticles in mice. J Pharm Sci 1995; 84(10): 1249-1253.
[35] Page ME, Pinto-Alphandary H, Chachaty E, Andremont A, Couvreur P. Entrapment of colistin into polyhexylcyanoacrylate nanoparticles: preparation, drug release and tissue distribution in mice. STP Pharm Sci 1996; 6(4): 298-301.
[36] Chem J-H, Wang L, Ling R, Li Y, Wang Q, Yao Z, Ma Z. Body distribution of nanoparticle containing adriamycin injected into the hepatic artery of hepatoma-bearing rats. Dig Dis Sci 2004; 49(7-8): 1170-1173.
[37] Teng KY, Lu Z, Wientjes MG, Au JL-S. Formulating paclitaxel in nanoparticles alters its disposition. Pharm Res 2005; 22(6): 867-874.
[38] Leu D, Manthey B, Kreuter J. Distribution and elimination of coated polymethyl [2-14C]methacrylate nanoparticles after intravenous injection in rats. J Pharm Sci 1984; 73(10): 1433-1437.
[39] Green MR, Manikhas GM, Orlov S, Afanasyev B, Makhson AM, Bhar P, Kawkins MJ. Abraxane®, a novel Cremophor®-free, albumin-bound particle form of paclitaxel for the treatment of advanced non-small-cell lung cancer. Ann Oncol 2006; 17(8): 1263-1268.
[40] Cryan S-A. Carrier based strategies for targeting protein and peptide drugs to the lungs. The AAPS J 2005; 7(1): E20-E41.
[41] Yanagihara K, Cheng PW. Lectin enhancement of the lipofection efficiency in human lung carcinoma cells. Biochim Biophys Acta 1999; 1472:25-33.
[42] Fajac I, Briand P, Monsigny M, Midoux P. Sugar-mediated uptake of glycosylated polylysines and gene transfer into normal and cystic fibrosis airway epithelial cells. Human Gene Ther 1999; 10: 395-406.
[43] Fajac I, Thevenot G, Bedouet L. Uptake of plasmid/glycosylated polymer complexes and gene transfer efficiency in differentiated airway epithelial cells. J Gene Med 2003; 5: 38-48.
[44] Derrien D, Midoux P, Petit C. Muramyl dipeptide bound to poly-L-lysine substituted with mannose and gluconoyl residues as macrophage activators. Glycoconj J 1989; 6: 241-255.
[45] Liang WW, Shi X, Deshpande D, Malanga CJ, Rojanasakul Y. Oligonucleotide targeting to alveolar macrophages by mannose receptormediated endocytosis. Biochim Biophys Acta 1996; 1279: 227-234.
[46] Harrison J, Shi X, Wang L, Ma JK, Rojanasakul Y. Novel delivery of antioxidant enzyme catalase to alveolar macrophages by Fc receptormediated endocytosis. Pharm Res 1994; 11: 1110-1114.
[47] Rojanasakul Y, Wang LY, Malanga CJ, Ma JK, Liaw J. Targeted gene delivery to alveolar macrophages via Fc receptor-mediated endocytosis. Pharm Res 1994; 11: 1731-1736.
[48] Briscoe P, Caniggia I, Graves A. Delivery of superoxide dismutase to pulmonary epithelium via pH-sensitive liposomes. Am J Physiol 1995; 268: L374-L380.
[49] Ross GF, Morris RE, Ciraolo G. Surfactant protein A-polylysine conjugates for delivery of DNA to airway cells in culture. Human Gene Ther 1995; 6: 31-40.
[50] Walther FJ, David-Cu R, Supnet MC, Longo ML, Fan BR, Bruni R. Uptake of antioxidants in surfactant liposomes by cultured alveolar type II cells is enhanced by SP-A. Am J Physiol 1993; 265: L330-L339.
[51] Frederiksen KS, Abrahamsen N, Cristiano RJ, Damstrup L, Poulsen HS. Gene delivery by an epidermal growth factor/DNA polyplex to small cell lung cancer cell lines expressing low levels of epidermal growth factor receptor. Cancer Gene Ther 2000; 7: 262-268.
[52] Cristiano RJ, Roth JA. Epidermal growth factor mediated DNA delivery into lung cancer cells via the epidermal growth factor receptor. Cancer Gene Ther 1996; 3: 4-10.
[53] Yanagihara K, Cheng H, Cheng PW. Effects of epidermal growth factor, transferrin, and insulin on lipofection efficiency in human lung carcinoma cells. Cancer Gene Ther 2000; 7: 59-65.
[54] Gladysheva IP, Moroz NA, Karmakova TA, Nemtsova ER, Yakubovskaya RI, Larionova NI. Immunoconjugates of soybean Bowman-Birk protease inhibitor as targeted antitumor polymeric agents. J Drug Target 2001; 9: 303-316.
[55] Mastrobattista E, Storm G, Van Bloois L. Cellular uptake of liposomes targeted to intercellular adhesion molecule-1 (ICAM-1) on bronchial epithelial cells. Biochim Biophys Acta 1999; 1419: 353-363.
[56] Jost PJ, Harbottle RP, Knight A, Miller AD, Coutelle C, Schneider H. A novel peptide, THALWHT, for the targeting of human airway epithelia. FEBS Lett 2001; 489: 263-269.
[57] Schneider H, Harbottle RP, Yokosaki Y, Jost P, Coutelle C. Targeted gene delivery into alpha9beta1-integrin-displaying cells by a synthetic peptide. FEBS Lett 1999; 458: 329-332.
[58] Scott ES, Wiseman JW, Evans MJ, Colledge WH. Enhanced gene delivery to human airway epithelial cells using an integrin-targeting lipoplex. J Gene Med 2001; 3: 125-134.
[59] Kreda SM, Pickles RJ, Lazarowski ER, Boucher RC. G-protein coupled receptors as targets for gene transfer vectors using natural small molecule ligands. Nat Biotechnol 2000; 18: 635-640.
[60] Reddy JA, Low PS. Folate-mediated targeting of therapeutic and imaging agents to cancers. Crit Rev Ther Drug Carrier Syst 1998; 15: 587-627.
[61] Deshpande D, Toledo-Velasquez D, Wang LY, Malanga CJ, Ma JK, Rojanasakul Y. Receptor-mediated peptide delivery in pulmonary epithelial monolayers. Pharm Res 1994; 11: 1121-1126.
[62] Franks TJ, Colby TV, Travis WD, Tuder RM, Reynolds HY, Brody AR, Cardoso WV, Crystal RG, Drake CJ, Engelhardt J. Resident cellular components of the human lung: current knowledge and goals for research on cell phenotyping and function. Proc Am Thorac Soc 2008; 5: 763–766.
[63] Giordano RJ, Edwards JK, Tuder RM, Arap W, Pasqualini R. Combinatorial ligand-directed lung targeting. Proc Am Thoracic Soc 2009; 6: 411-415.
[64] Cheng J, Teply BA, Sherifi I, Sung J, Luther G, Gu FX, Levy-Nissenbaum E, Radovic-Moreno AF, Langer R, Farokhzad OC. Formulation of functionalized PLGA-PEG nanoparticles for in vivo targeted drug delivery. Biomaterials 2007; 28: 869-876.
[65] Reddy LH, Murthy RSR. Etoposide loaded nanoparticles made from glyceride lipids: formulation, characterization, in vitro drug release and stability evaluation. AAPS PharmSciTech 2005; 6(2): E158-E166
[66] Lepoittevin B, Masson S, Huc V, Haut C, Roger P. Synthesis and characterization of glycosylated nanoparticles. E-polymers 2006; 32: 1-15.
[67] Lee SH, Zhang Z, Feng S-S. Nanoparticles of poly(lactide)-tocopheryl polyethylene glycol succinate (PLA-TPGS) copolymers for protein drug delivery. Biomaterials 2007; 28: 2041-2050.
[68] Gao F-P, Zhang H-Z, Liu L-R, Wang Y-S, Jiang Q, Zhang Q-Q. Preparation and physicochemical characteristics of deoxycholic modified carboxymethyl curdlan conjugates. Carbohyrate Polymers 2008; 71(4): 606-613.
[69] Paranjape PV, Chen Y, Kholodovych V, Welsh D, Stein S, Sinko PJ. Tumor-targeted bioconjugate based delivery of Camptothecin: design, synthesis and in vitro evaluation. J Control Release 2004; 100(2): 275-292.
[70] Jain A, Agrawal A, Majumder S, Lariya N, Khaya A, Agrawal H, Majumdar S, Agrawal GP. Mannosylated solid-lipid nanoparticles as vectors for site-specific delivery of an anti-cancer drug. J Control Release 2010; 148(3): 359-367.
[71] Chandna P, Saad M, Wang Y, Wer E, Khandare J, Vetcher AA, Soldatenkov VA, Minko T. Targeted proapoptotic anticancer drug delivery system. Mol Pharm 2007; 4(5): 668–678.
[72] Park EK, Lee SB, Lee YM. Preparation and characterization of methoxy poly(ethylene glycol)/poly (ε-caprolactone) amphiphilic block coplymeric nanospheres for tumor-specific folate mediated targeting of anticancer drugs. Biomaterials 2005; 26: 1053-1061.
[73] Park K, Lee GY, Kim Y-S, Yu M, Park R-W, Kim I-S, Kim SY, Byun Y. Heparin-deoxycholic acid chemical conjugate as an anticancer drug carrier and its antitumor activity. J Control Release 2006; 114: 300–306.
[74] Bozkir A, Saka AM. Formulation and evaluation of 5-FU nanoparticles with factorialdesign based studies. Farmaco 2005; 60(10): 840-846.
[75] Maghsoudi A, Shojaosadati SA, Vasheghani-Farahani E. 5-fluorouracil loaded BSA nanoparticles: Formulation optimization and in vitro release study. AAPS PharmaSciTech 2008; 9(4): 1092-1096.
[76] Zhang D-Y, Shen X-Z, Wanf J-Y, Dong L, Zheng Y-L, Wu L-L. Preparation of chitosan-polyaspartic acid-5-fluorouracil nanoparticles and its anti-carcinoma effect on tumor growth in nude mice. World J Gastroenterol 2008; 14(22): 3554-3562.
[77] Yassin AEB, Anwer MD, Mowafy HA, El-Bagory IM, Bayomi MA, Alsarra IA. Optimization of 5-fluorouracil solid-lipid nanoparticles: a preliminary study to treat colon cancer. Int J Med Sci 2010; 7(6): 398-408.
[78] Tosi G, Bortot B, Ruozi B, Dolcetta D, Vandelli MA, Forni F, Severini GM. Potential use of polymeric nanoparticles for drug delivery across the blood brain barrier. Curr Med Chem 2013; 20(17): 22112-22125.
[79] Cho JK, Park BD, Lee YS. A novel core-shell type polymer support for solid-phase peptide synthesis. Tet Lett 2000; 41: 7481-7485
[80] Yu DH, Lu Q, Xie J, Fang C, Chen HZ. Peptide-conjugated biodegradable nanoparticles as a carrier to target paclitaxel to tumor neurovasculature. Biomaterials 2010; 31 (8): 2278-2292
[81] Dubey N, Varshney R, Shukla J, Ganeshpurkar A, Hazari PP, Bandopadhyay GP, Mishra AK, Trivedi P. Synthesis and evaluation of biodegradable PCL/PEG nanoparticles for neuroendocrine tumor targeted delivery of somatostatin analog. Drug Del 2012; 19: 132-142
[82] Danhier F, Lecouturier N, Vroman B, Jerome C, Marchand-Brynaert J, Feron O, Preat V. Paclitaxel loaded PEGylated PLGA based nanoparticles: In vitro and in vivo evaluation. J Control Release 2009; 133: 11-17
[83] Kuo G, Gao J, Wang H, Chen H, Li B, Zhang D et al. Preparation and characterization of paclitaxel-loaded PLGA nanoparticles coated with cationic SM5-1 single-chain antibody. J Biochem Mol Bio 2007; 40 (5): 731-739
